https://allsci.com/news/regulatory-setbacks-safety/anaphylm-nda-fda-resubmission-aquestive-resubmits/ AllScien 2026-09-21T14:26:17.718606Z Anaphylm returns to FDA after Aquestive addresses usability, PK concerns https://allsci.com/news/clinical-trials/xlrp-gene-therapy-beacons-laru-zova-becomes-first/ AllScien 2026-09-21T14:19:25.255448Z Beacon's laru-zova becomes first XLRP gene therapy to meet pivotal trial primary endpoint https://allsci.com/news/development/azetukalner-fda-approval-focal-seizures/ AllScien 2026-09-21T13:09:00.718453Z Xenon files azetukalner NDA for focal seizures as KV7 revival, pauses psychiatry trials https://allsci.com/news/clinical-trials/cue-221-phase-ii-csu-cues-meets-primary-endpoint/ AllScien 2026-09-21T12:38:24.494585Z Cue’s anti-IgE antibody CUE-221 meets Phase II endpoints in chronic urticaria https://allsci.com/news/china-pharmaceutical-five-year-plan-chinas-ten/ AllScien 2026-09-21T12:06:26.376836Z China targets 25% of global first-in-class drugs by 2030 in new pharma five-year-plan https://allsci.com/news/clinical-trials/tyk2-inhibitor-psoriasis-hansohs-hs-10374-meets/ AllScien 2026-09-21T11:27:03.087282Z Hansoh's TYK2 inhibitor HS-10374 meets Phase III endpoints in moderate-to-severe psoriasis https://allsci.com/news/clinical-trials/atg-022-phase-iii-trial-gastric-cancer-antengene/ AllScien 2026-09-21T11:06:39.476952Z Antengene launches pivotal Phase III trial of ATG-022 in third-line gastric cancer https://allsci.com/news/clinical-trials/lavengratinib-achondroplasia-trial-abbiskos/ AllScien 2026-09-21T10:29:22.663060Z Abbisko's lavengratinib achieves 100% responder rate in early achondroplasia trial https://allsci.com/news/telix-itm-acquisition-radioisotope-acquires/ AllScien 2026-09-21T10:18:56.167117Z Telix acquires ITM Isotope Technologies for USD 1.65b to secure radioisotope supply chain https://allsci.com/news/regulatory-policy/pharma-licensing-deals-china-us-treasury-drafts/ AllScien 2026-09-21T10:06:32.472403Z US Treasury reportedly drafting rules to preserve pharma licensing deals with China https://allsci.com/news/licensing-and-partnerships/novo-nordisk-obesity-acquisition-acquires-three/ AllScien 2026-09-21T08:53:37.077928Z Novo acquires three early-stage obesity programs from Columbia-linked Kallyope